Founded in 2013 and based in San Diego, Arcturus Therapeutics Ltd. is a publicly traded RNA medicines company. We are developing a portfolio of RNA therapeutics for the treatment of diseases with high unmet medical needs. Our team has extensive experience in the discovery and development of RNA medicines, as well as the design and utilization of lipid-mediated drug delivery systems. This combination of in-house expertise, innovative spirit, and passion for what we do, uniquely positions us to catalyze the next generation of RNA medicines. Arcturus’ commitment to the development of novel RNA therapeutics has led to partnerships with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, Synthetic Genomics Inc., CureVac AG, and the Cystic Fibrosis Foundation.